Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDAGet Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, January 21st.

Get Our Latest Stock Analysis on VNDA

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA opened at $4.45 on Tuesday. The firm’s fifty day moving average is $4.74 and its two-hundred day moving average is $5.00. The firm has a market cap of $259.47 million, a price-to-earnings ratio of -15.89 and a beta of 0.77. Vanda Pharmaceuticals has a one year low of $3.46 and a one year high of $6.75.

Insider Buying and Selling

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the sale, the director now owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.90% of the company’s stock.

Institutional Trading of Vanda Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Verition Fund Management LLC raised its holdings in Vanda Pharmaceuticals by 7.8% in the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 2,927 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Vanda Pharmaceuticals by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after buying an additional 3,473 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 4,374 shares during the period. Franklin Resources Inc. grew its stake in shares of Vanda Pharmaceuticals by 8.8% in the 3rd quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 4,449 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Vanda Pharmaceuticals by 26.8% in the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 5,459 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

(Get Free Report)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Read More

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.